Sava Raises $19M in Series A Funding to Advance Next-Gen Biosensor
Deal News | Jul 31, 2025 | Balderton Capital
Sava, a startup based in London, has announced a successful Series A funding round of $19 million. This funding was led by Balderton Capital and Pentland Ventures, with participation from Norrsken VC, JamJar Investments, and others. Founded in 2019 by bioengineers from Imperial College London, Sava is focused on developing a next-generation biosensor for real-time molecular health monitoring. Their device has shown promising results in a clinical trial, being able to monitor glucose levels continuously for up to 10 days, surpassing current alternatives. Sava's technology aims to redefine chronic disease management by making Continuous Glucose Monitors (CGMs) more accessible and cost-effective. With their platform capable of multi-molecule sensing, Sava is poised to lead in preventative and personalized healthcare. The investment will help Sava progress toward regulatory approvals, commercialize their biosensor, and expand their team and manufacturing capabilities.
Sectors
- Healthcare Technology
- Wearable Technology
- Venture Capital
Geography
- United Kingdom – Sava is a London-based startup and many clinical trials are conducted in Oxford and Cambridge, highlighting the UK focus.
Industry
- Healthcare Technology – Sava is developing a biosensor device for healthcare monitoring, which places it squarely within the realm of healthcare technology.
- Wearable Technology – Sava's biosensor device is a wearable, designed to provide real-time health data, aligning with the wearable tech industry.
- Venture Capital – The article discusses venture capital firms investing in Sava's funding round, making VC a relevant classification.
Financials
- $19 million – The amount raised by Sava in Series A funding.
- $32 million – The total funding Sava has raised to date.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Sava | Target company | Company | A startup focused on developing real-time molecular health monitoring technology. |
| Balderton Capital | Lead Investor | Company | A venture capital firm that led the Series A funding round for Sava. |
| Pentland Ventures | Co-investor | Company | A firm participating in Sava's Series A funding round. |
| Norrsken VC | Investor | Company | A new investor in Sava's Series A funding. |
| JamJar Investments | Investor | Company | A new participant in Sava's Series A funding round. |
| Renato Circi | Co-founder | Person | A bioengineer from Imperial College London and co-founder of Sava. |
| Rafal Michali | Co-founder | Person | A bioengineer from Imperial College London and co-founder of Sava. |
| James Wise | Partner | Person | A partner at Balderton Capital. |